Weekly Recap | Leidos -0.91%, consensus target above spot
I'm LongbridgeAI, I can summarize articles.Leidos fell 0.91% this week, closing at $127.69. The S&P 500 slipped 0.08%, so the stock underperformed by roughly 0.83 percentage point. The daily bars show a fade after an early spike: Monday (Sep 14) pushed up to a high of $133.91 and closed at $132.83, Tuesday (Sep 15) traded as high as $133.925 before pulling back, and Friday (Sep 18) slid to $127.25 to finish near the week’s low. Trading volume across the week came in above the recent median.
The Week
Leidos fell 0.91% this week, closing at $127.69. The S&P 500 slipped 0.08%, so the stock underperformed by roughly 0.83 percentage point. The daily bars show a fade after an early spike: Monday (Sep 14) pushed up to a high of $133.91 and closed at $132.83, Tuesday (Sep 15) traded as high as $133.925 before pulling back, and Friday (Sep 18) slid to $127.25 to finish near the week’s low. Trading volume across the week came in above the recent median.
Key Events
The most concrete company development came on Saturday, Sep 19, when Leidos was reported to have won an $85 million U.S. Air Force contract. That news landed after the trading week ended, so it was not reflected in the five sessions covered here. Midweek reports painted a mixed picture on relative strength: a Wednesday item noted the stock underperformed peers on Tuesday, while a Friday item described a strong trading day that outperformed competitors. On Tuesday, Leidos also appeared alongside AstraZeneca and Expeditors in market commentary, though that was more about sentiment than any company-specific catalyst.
Analyst Ratings
Leidos is covered by 17 analysts: 4 rate it buy, 3 overweight, and 10 hold. There are no underweight or sell ratings. The consensus recommendation is buy, and the consensus target price is $157.27, roughly 23.2% above the latest close. Targets range from $132 to $225, a wide spread that points to real disagreement on valuation. Within the research and consulting services industry, Leidos ranks 5th out of 40 companies in analyst rating consensus.
The Week Ahead
Next week’s macro calendar runs from Tuesday to Thursday. Sep 22 brings the Richmond Fed composite index, Sep 23 brings EIA weekly crude oil and Cushing crude inventory data, and Sep 24 brings jobless claims, the current account balance, new home sales annual rate, and EIA natural gas inventory changes. Leidos itself has no scheduled earnings or company events, so the stock is likely to track broader U.S. macro data and defence-sector sentiment.
In Short
The key tension this week sits between a broadly constructive analyst picture and a stock that faded after an early spike. The consensus target price is more than 20% above spot, with most ratings clustered in buy and hold, yet the shares closed lower and lagged the index. Large-lot money was a net buyer in the latest session while medium and small-lot flows sold. The weekend Air Force contract is a concrete item to watch, but the market has not yet had a chance to price it.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.
